Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News EMBRACE results prompt Sobi to engage regulators on emapalumab sepsis pathway Sobi will advance emapalumab in IFNγ-driven sepsis after EMBRACE trial shows proof-of-concept. Find out what this pivot means for its strategy and the field. byVenkateshJanuary 9, 2026